Related Experiment Video
Updated: Mar 30, 2026
In Vitro Cultivation Techniques for Modeling Liver Organogenesis, Building Assembloids, and Designing Synthetic Tissues using Human Cell Lines
Published on: April 18, 2025
miR-128 modulates hepatocellular carcinoma by inhibition of ITGA2 and ITGA5 expression
Xiaohua Zhao1, Yingfen Wu2, Zhiping Lv3
1School of Traditional Chinese Medicine, Southern Medical University Guangzhou, China ; Kangwei Hospital Xinji, China.
Abstract:
Dysregulation of miRNAs is a common feature in human cancers, but this phenomenon has not been studied extensively in hepatocellular carcinoma (HCC). miR-128 has been found to be downregulated in cancer. However its role in HCC remains unclear. miR-128 was underexpressed in HCC tissues and cell lines compared with their normal controls. Additionally, ITGA2 and ITGA5 were predicted as the target genes of miR-128. ITGA2 and ITGA5 were inversely correlated with the expression of miR-128 in HCC cells. Importantly, we demonstrate that the overexpression of miR-128 significantly inhibits HCC cell metastasis and stem-cell like properties via ITGA2 and ITGA5. Our results suggest the existence of a novel miR-128-ITGA pathway and indicate that miR-128 acts as a tumor suppressor during hepatocellular carcinogenesis. These results may provide a promising alternative strategy for the therapeutic treatment of HCC.
Insights
MicroRNA-128 (miR-128) is underexpressed in hepatocellular carcinoma (HCC), inhibiting cancer metastasis and stem-like properties by targeting ITGA2 and ITGA5. This suggests miR-128 acts as a tumor suppressor in HCC development.
Area of Science:
- Molecular Biology
- Oncology
- Genetics
Background:
- MicroRNA (miRNA) dysregulation is implicated in human cancers, but its specific role in hepatocellular carcinoma (HCC) is not well understood.
- While miR-128 is known to be downregulated in various cancers, its function in HCC pathogenesis remains largely unelucidated.
- Investigating novel molecular pathways is crucial for advancing HCC therapeutic strategies.
Purpose of the Study:
- To investigate the expression and function of miR-128 in hepatocellular carcinoma (HCC).
- To identify and validate the target genes of miR-128 in HCC.
- To elucidate the role of the miR-128-ITGA pathway in HCC progression and metastasis.
Main Methods:
- Quantitative real-time PCR (qRT-PCR) to assess miR-128 expression in HCC tissues and cell lines.
- Bioinformatic prediction and luciferase reporter assays to identify miR-128 target genes.
- Western blotting and cell-based assays to evaluate the effects of miR-128 overexpression on HCC cell metastasis and stemness, focusing on ITGA2 and ITGA5.
Main Results:
- miR-128 expression was significantly downregulated in HCC tissues and cell lines compared to normal controls.
- ITGA2 and ITGA5 were identified as direct target genes of miR-128 and showed an inverse correlation with miR-128 levels in HCC cells.
- Overexpression of miR-128 suppressed HCC cell migration, invasion, and stem-cell-like properties, mediated through the downregulation of ITGA2 and ITGA5.
Conclusions:
- A novel tumor-suppressive pathway involving miR-128 targeting ITGA2 and ITGA5 in hepatocellular carcinoma (HCC) was identified.
- miR-128 functions as a tumor suppressor in hepatocellular carcinogenesis, inhibiting metastasis and stemness.
- The miR-128-ITGA pathway presents a potential therapeutic target for hepatocellular carcinoma (HCC) treatment.
Related Concept Videos
01:22MicroRNAs
01:22MicroRNAs